WO2002047649A1 - Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un carotenoide - Google Patents
Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un carotenoide Download PDFInfo
- Publication number
- WO2002047649A1 WO2002047649A1 PCT/FR2001/003643 FR0103643W WO0247649A1 WO 2002047649 A1 WO2002047649 A1 WO 2002047649A1 FR 0103643 W FR0103643 W FR 0103643W WO 0247649 A1 WO0247649 A1 WO 0247649A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dhea
- composition according
- carotenoid
- composition
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- the present invention relates to a composition containing 7-hydroxy DHEA and / or 7-keto DHEA and at least one carotenoid, as well as to the use of said composition, in particular for preventing or treating signs of actinic skin aging .
- DHEA dehydroepiandrosterone
- Exogenous DHEA administered topically or orally, is known for its ability to promote keratinization of the epidermis (JP-07
- 7-hydroxy DHEA is, with 5-androstene 3 ⁇ , 17 ⁇ -diol, a major metabolite of DHEA, obtained by the action of 7 ⁇ -hydroxylase on DHEA.
- minor metabolites of DHEA mention may be made of 7 ⁇ -hydroxy DHEA, obtained by the action of 7 ⁇ - hydroxylase on DHEA and 7-keto DHEA, which is itself a metabolite of 7 ⁇ -hydroxy DHEA.
- a subject of the present invention is therefore a composition containing, in a physiologically acceptable medium: (a) at least one DHEA derivative chosen from 7-hydroxy DHEA and 7-keto DHEA, and (b) at least one carotenoid.
- the 7-hydroxy DHEA is preferably 7 -OH DHEA.
- a process for the preparation of this compound is described in particular in patent applications FR-2 771 105 and WO 94/08588.
- 7 ⁇ -OH DHEA is also suitable for use in the present invention.
- the concentration of DHEA derivative in the composition according to the invention is advantageously between 0.0000001% and 10% by weight, preferably between 0.00001% and 5% by weight, relative to the total weight of the composition.
- composition according to the present invention contains, in combination with the DHEA derivative, at least one carotenoid.
- carotenoid is meant according to the invention both a carotenoid with provitamin A activity, and a carotenoid without provitamin A activity.
- ⁇ -carotene Among the carotenoids without provitamin A activity, there may be mentioned, by way of example, zeaxanthin, lutein or lycopene.
- the carotenoid used according to the invention can be of natural or synthetic origin.
- natural origin is meant the carotenoid, in the pure state or in solution whatever its concentration in said solution, obtained from a natural element.
- synthetic origin is meant the carotenoid, in the pure state or in solution whatever its concentration in said solution, obtained by chemical synthesis.
- the carotenoid When the carotenoid is of natural origin, it can be obtained from plant material from a whole plant grown in vivo or from in vitro culture.
- in vivo culture means any culture of the conventional type, that is to say in soil in the open air or in a greenhouse, or even above ground.
- in vitro culture means all of the techniques known to a person skilled in the art which makes it possible artificially to obtain a plant or part of a plant. The selection pressure imposed by the physico-chemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant material which is available throughout the year unlike plants cultivated in vivo.
- a plant derived from culture in vivo is used.
- the carotenoid can be in alcoholic solution, in particular ethanolic.
- the carotenoid can also be in lipid (oil) or lipoalcoholic solution.
- the preferred carotenoids according to the invention are ⁇ -carotene and lycopene. Very preferably, lycopene is used.
- Lycopene is a natural pigment found in ripe fruit, especially in tomatoes. Its structure is close to that of ⁇ -carotene. It can be in cis or trans form.
- a tomato extract rich in lycopene is used, prepared by the company Métaphar, marketed under the name LycOMato® consisting of an oleoresin extract (fatty phase) containing 6% of pure lycopene.
- LycOMato® consisting of an oleoresin extract (fatty phase) containing 6% of pure lycopene.
- the amount of carotenoid that can be used according to the invention is of course a function of the desired effect and can therefore vary to a large extent.
- the carotenoid in the pure state is in an amount representing from 10 "12 % to 20% of the total weight of the composition and preferably in an amount representing from 10 " 8 % to 10% of the total weight of the composition.
- Lycopene is notably known as an anti-radical agent (JP-A-8-283136).
- 7 ⁇ -OH DHEA applied topically, itself has an activity on the signs of skin aging, due in particular to its anti-radical effects.
- composition according to the invention is preferably suitable for topical application to the skin. It can be in all dosage forms normally used for this type of application, in particular in the form of an aqueous or oily solution, an oil-in-water or water-in-oil or multiple emulsion, a silicone emulsion, a microemulsion or nanoemulsion, an aqueous or oily gel or a liquid, pasty or solid anhydrous product.
- This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. or a gel. It can optionally be applied to the skin in the form aerosol. It can also be in solid form, and for example in the form of a stick. It can be used as a care product and / or as a skin makeup product.
- the composition of the invention may also contain the adjuvants usual in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, pigments, odor absorbers and coloring matter.
- the amounts of these various adjuvants are those conventionally used in the fields under consideration, and for example from 0.01 to 20% of the total weight of the composition.
- These adjuvants depending on their nature, can be introduced into the fatty phase or into the aqueous phase.
- These adjuvants, as well as their concentrations must be such that they do not harm the advantageous properties of the DHEA derivatives, nor of the carotenoids according to the invention.
- the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition.
- the fats, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration.
- the emulsifier and the coemulsifier are preferably present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.
- oils and in particular mineral oils such as mineral oils (petroleum jelly oil), oils of vegetable origin (avocado oil, soybean oil), oils of animal origin (lanolin) can be used.
- synthetic oils perhydrosqualene
- silicone oils cyclomethicone
- fluorinated oils perfluoropolyethers.
- Fatty alcohols such as cetyl alcohol, fatty acids, waxes and gums and in particular silicone gums can also be used as fats.
- emulsifiers and coemulsifiers which can be used in the invention, there may be mentioned, for example, fatty acid esters of polyethylene glycol such as PEG-100 stearate, PEG-50 stearate and PEG-40 stearate; fatty acid esters and of polyols such as glyceryl stearate, sorbitan tristearate and sorbitan stearates oxyéthyi mares available under the tradenames Tween ® 20 or Tween ® 60, for example; and their mixtures.
- polyethylene glycol such as PEG-100 stearate, PEG-50 stearate and PEG-40 stearate
- fatty acid esters and of polyols such as glyceryl stearate, sorbitan tristearate and sorbitan stearates oxyéthyi mares available under the tradenames Tween ® 20 or Tween ® 60, for example; and their mixtures.
- hydrophilic gelling agents mention may in particular be made of carboxyvinyl polymers (carbomers), acrylic copolymers such as. acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids and hydrophobic silica.
- the composition can be adapted for oral administration.
- it can be in the form of syrups, suspensions, solutions, emulsions, granules, capsules or tablets, for example.
- the daily doses of DHEA derivative administered orally can be between 1 and 100 mg / day, preferably between 25 and 75 mg / day.
- the DHEA derivative is present in the composition according to the invention in an amount allowing its administration at a dose of between 50 and 100 mg / day, said dosage being carried out in one or more doses, with a unit dose of 50 mg. .
- the daily doses of carotenoids administered orally must be defined on a case-by-case basis, depending on the carotenoid concerned. More particularly in the case of Beta-Carotene or Lycopene, the daily doses administered may be between 1 and 500 mg / day. Preferably at doses between 1 and 50 mg / day.
- composition according to the invention and / or the preparation obtained from it comprises an effective amount of DHEA derivative and an effective amount of carotenoid, sufficient to obtain the desired effect, in a physiologically medium acceptable.
- the composition according to the invention finds in particular an application in the prevention and the treatment of the signs of skin aging, in particular of. actinic aging.
- the present invention therefore also relates to the cosmetic use of the composition mentioned above for preventing or treating the signs of skin aging, in particular of actinic aging.
- composition described above for preventing or combating the formation of wrinkles and / or for improving the tone of the skin and / or for increasing the firmness of the skin.
- the present invention also relates to the cosmetic use of the composition described above for preventing or combating the harmful effects of UV rays on the skin.
- composition described above for manufacturing a preparation intended to prevent or combat the harmful effects of U V on the skin.
- Soft capsules are prepared, conventionally for those skilled in the art, having the following composition:
- Soft capsules are prepared, conventionally for those skilled in the art, having the following composition:
- Example 3 Composition for topical application
- a treatment cream oil-in-water emulsion having the following composition is prepared, conventionally for a person skilled in the art:
- Polysorbate 60 (Tween 60 ® sold by the company ICI) 1%
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002220804A AU2002220804A1 (en) | 2000-12-15 | 2001-11-20 | Composition containing 7-hydroxy dhea and/or 7-keto dhea and at least a carotenoid |
EP01270314A EP1343467A1 (fr) | 2000-12-15 | 2001-11-20 | Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un carotenoide |
JP2002549224A JP2004518645A (ja) | 2000-12-15 | 2001-11-20 | 7−ヒドロキシ−dheaおよび/または7−ケト−dheaおよび少なくとも一つのカロテノイドを含む組成物 |
US10/433,490 US6994864B2 (en) | 2000-12-15 | 2001-11-20 | Composition containing 7-hydroxy DHEA and/or 7-keto DHEA and at least a carotenoid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR00/16436 | 2000-12-15 | ||
FR0016436A FR2818135B1 (fr) | 2000-12-15 | 2000-12-15 | Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un carotenoide |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002047649A1 true WO2002047649A1 (fr) | 2002-06-20 |
Family
ID=8857751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/003643 WO2002047649A1 (fr) | 2000-12-15 | 2001-11-20 | Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un carotenoide |
Country Status (6)
Country | Link |
---|---|
US (1) | US6994864B2 (fr) |
EP (1) | EP1343467A1 (fr) |
JP (1) | JP2004518645A (fr) |
AU (1) | AU2002220804A1 (fr) |
FR (1) | FR2818135B1 (fr) |
WO (1) | WO2002047649A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2818148B1 (fr) * | 2000-12-15 | 2005-06-24 | Oreal | Composition,notamment cosmetique, renfermant, la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoide |
EP2116223B1 (fr) * | 2007-01-05 | 2015-12-09 | FUJIFILM Corporation | Composition de dispersion, préparation cosmétique pour un soin de la peau, et procédé de fabrication d'une composition de dispersion |
US20090162306A1 (en) * | 2007-12-21 | 2009-06-25 | Conopco, Inc., D/B/A Unilever | Topical composition comprising coloring antioxidants |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998003170A1 (fr) * | 1996-07-24 | 1998-01-29 | Biosytes Usa, Inc. | Procede d'accentuation des caracteristiques de dissolution de complements alimentaires relativement insolubles et produits incorporant ces complements |
FR2771105A1 (fr) * | 1997-11-20 | 1999-05-21 | Vitasterol | Utilisation du fusarium monoliforme pour la preparation des derives 7alpha-hydroxyles de la dehydroepiandrosterone et de la pregnenolone |
US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
US6093706A (en) * | 1992-03-04 | 2000-07-25 | Bioresponse, L.L.C. | Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU647528B2 (en) | 1990-08-29 | 1994-03-24 | Humanetics Corporation | Treatment process for promoting weight loss employing a substituted delta5-androstene |
DE4432947C2 (de) | 1994-09-16 | 1998-04-09 | New Standard Gmbh | Mittel zur Behandlung der Haut und seine Verwendung |
DE4444238A1 (de) * | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden |
ES2098193B1 (es) | 1995-07-21 | 1997-12-01 | Gomez Jesus Calderon | Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea. |
FR2760362B1 (fr) | 1997-03-10 | 2000-08-11 | Vitasterol | Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles |
US6060070A (en) | 1997-06-11 | 2000-05-09 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
FR2765803B1 (fr) | 1997-07-11 | 2002-07-19 | Ng Payot Lab Dr | Composition cosmetique ou dermopharmaceutique pour application topique |
WO1999007381A1 (fr) | 1997-08-11 | 1999-02-18 | Weider Nutrition International, Inc. | Compositions et traitements permettant de reduire les effets secondaires lies a l'administration des precurseurs de la testosterone androgenique |
EP0908183A1 (fr) | 1997-10-08 | 1999-04-14 | Institute For Advanced Skin Research Inc. | Déhydroépiandrostérone ou ses dérivés pour augmenter la quantité d'acide hyaluronique dans la peau |
FR2777182B1 (fr) | 1998-04-10 | 2000-06-30 | Lvmh Rech | Compositions cosmetiques ou dermotalogiques pour application topique sous forme d'emulsions de type huile-dans-eau renfermant des esters liquides d'acide gras et d'alcool gras et des phospholipides et leur procede de preparation |
JP2002519366A (ja) | 1998-07-07 | 2002-07-02 | トランスダーマル・テクノロジーズ・インコーポレーテツド | 医薬的に活性な作用物質を迅速かつ非刺激的に経皮送達するための組成物、およびそのような組成物の調剤法およびそれらの送達 |
WO2000028996A1 (fr) | 1998-11-19 | 2000-05-25 | Mrs, Llc | Utilisation cosmetique ou dermatologique de steroides 7-hydroxylates seuls ou combines ave des peptides derives de l'elastine |
FR2818148B1 (fr) | 2000-12-15 | 2005-06-24 | Oreal | Composition,notamment cosmetique, renfermant, la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoide |
-
2000
- 2000-12-15 FR FR0016436A patent/FR2818135B1/fr not_active Expired - Fee Related
-
2001
- 2001-11-20 US US10/433,490 patent/US6994864B2/en not_active Expired - Fee Related
- 2001-11-20 WO PCT/FR2001/003643 patent/WO2002047649A1/fr not_active Application Discontinuation
- 2001-11-20 AU AU2002220804A patent/AU2002220804A1/en not_active Abandoned
- 2001-11-20 EP EP01270314A patent/EP1343467A1/fr not_active Withdrawn
- 2001-11-20 JP JP2002549224A patent/JP2004518645A/ja not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6093706A (en) * | 1992-03-04 | 2000-07-25 | Bioresponse, L.L.C. | Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders |
WO1998003170A1 (fr) * | 1996-07-24 | 1998-01-29 | Biosytes Usa, Inc. | Procede d'accentuation des caracteristiques de dissolution de complements alimentaires relativement insolubles et produits incorporant ces complements |
FR2771105A1 (fr) * | 1997-11-20 | 1999-05-21 | Vitasterol | Utilisation du fusarium monoliforme pour la preparation des derives 7alpha-hydroxyles de la dehydroepiandrosterone et de la pregnenolone |
US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
Also Published As
Publication number | Publication date |
---|---|
FR2818135A1 (fr) | 2002-06-21 |
FR2818135B1 (fr) | 2003-02-14 |
AU2002220804A1 (en) | 2002-06-24 |
JP2004518645A (ja) | 2004-06-24 |
US6994864B2 (en) | 2006-02-07 |
EP1343467A1 (fr) | 2003-09-17 |
US20040077722A1 (en) | 2004-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1090628B1 (fr) | Utilisation du lycopène dans des compositions destinées à traiter les signes cutanés du vieillissement | |
CA2357862A1 (fr) | Utilisation d'au moins un extrait d'au moins un vegetal de la famille des ericaceae, dans des compositions destinees a traiter les signes cutanes du vieillissement | |
FR2812544A1 (fr) | Utilisation d'au moins un extrait d'au moins un vegetal du genre salvia dans des compositions destinees a traiter les signes cutanes du vieillissement | |
EP0673238B1 (fr) | Utilisation d'un extrait de simarouba pour l'attenuation des taches pigmentaires de la peau | |
WO2002034233A2 (fr) | Utilisation de l'association d'un carotenoide et d'un isoflavonoide pour traiter les signes cutanes du vieillissement | |
EP1331924B1 (fr) | Utilisation de beta-carotene et de lycopene pour traiter les signes cutanes du vieillissement via l'inhibition de l'expression de la metalloproteinase de type 1 de la matrice extracellulaire | |
EP3077061B1 (fr) | Composition pour reduire les troubles de la senescence cutanee comprenant un rétinalaldéhyde et un extrait de leontopodium alpinum | |
EP1303253B1 (fr) | Composition, notamment cosmetique, comprenant la dhea et/ou un precurseur ou derive de celle-ci, en association avec au moins un agent anti-glycation | |
WO2002047649A1 (fr) | Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un carotenoide | |
WO2002034210A2 (fr) | Utilisation de l'association d'au moins un carotenoide et de vitamine c pour traiter les signes cutanes du vieillissement | |
WO2002005776A1 (fr) | Composition, notamment cosmetique, renfermant la dhea ou certaines de ses derives, et un carotenoïde | |
FR2859102A1 (fr) | Utilisation d'un extrait de rhodiola crenulata par voie topique | |
WO2012172218A2 (fr) | Complexe d'extraits végétaux pour la protection de la peau. | |
FR2815863A1 (fr) | Composition comprenant l'association d'au moins un extrait d'au moins un vegetal du genre rosmarinus et d'au moins un carotenoide | |
EP1316301A1 (fr) | Composition cosmétique ou dermatologique comprenant un rétinoide et/ou un caroténoide et l'acide acexamique. | |
FR2821549A1 (fr) | Utilisation d'un carotenoide pour traiter les signes du vieillissement | |
FR2815862A1 (fr) | Composition comprenant l'association d'au moins un extrait d'au moins un vegetal du genre camellia et d'au moins un carotenoide | |
WO2002047648A1 (fr) | Composition, notamment cosmetique, comprenant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent anti-glyction | |
FR3110421A1 (fr) | Extrait de Narcissus poeticus pour son utilisation cosmétique | |
WO2002047655A1 (fr) | Composition, notamment cosmetique, comprenant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un inhibiteur de no-synthase | |
WO2002047646A1 (fr) | Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins une vitamine et/ou un co-facteur enzymatique | |
WO2002047647A1 (fr) | Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent depigmentant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001270314 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002549224 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001270314 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10433490 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001270314 Country of ref document: EP |